As of Feb 12
| +0.02 / +2.27%|
The 3 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 3.50, with a high estimate of 5.00 and a low estimate of 3.00. The median estimate represents a +288.89% increase from the last price of 0.90.
The current consensus among 3 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.